CCTV+: A Pearl of Wisdom: Deqing's Aquaculture Legacy Gains Global Recognition
, May 22, 2025 /CNW/ -- On the crown of global agricultural heritage, a new jewel has been added. On May 19 , news broke from the Food and Agriculture Organization of the United Nations (FAO) that the Zhejiang Deqing Freshwater Pearl Mussel Composite Fishery System, known as the "Deqing Pearl System", has been added to the Globally Important Agricultural Heritage Systems (GIAHS) list for 2025. It becomes China's first world-class agricultural cultural heritage project in aquaculture.
Heritage under the Ministry of Agriculture and Rural Affairs, is the earliest-recorded area for freshwater pearl farming. As early as the Southern Song Dynasty, it achieved artificial freshwater pearl cultivation.
At Xiaoshanyang in Fuxi Street, fish glide and mussels nestle with clear water. The leftover fish feed and excrement cultivate plankton algae, which feed the pearl-bearing Mussels and purify the water in return, forming an ecological cycle. FAO expert Aicha Bammoun said the system is a model of combining agricultural wisdom with modern conservation, reflecting the enduring vitality of Chinese agricultural civilization.
In recent years, Deqing has been promoting the "pearl+" full-industry-chain integration. Currently, Deqing's pearl deep-processing industry generates an annual output value of over 7 billion yuan , accounting for about one-tenth of the national total and providing employment for nearly 20,000 people.
Back in the late 1970s, Deqing began the systematic research on the origin of freshwater pearl farming. After more than 30 years of literature research and field surveys, it produced a series of results like "Proof of the Origin of Large-scale Cultivation of Artificial Pearls in Ancient China". In June 2017 , the system was officially recognized as China's Important Agricultural Cultural Heritage by the Ministry of Agriculture and Rural Affairs. In September of the same year, Deqing launched the application for GIAHS. In 2019, it entered the GIAHS Preparatory List. In April this year, FAO experts conducted an on-site assessment in Deqing and finally confirmed its inclusion.
"As China's first GIAHS project in aquaculture, the Deqing Pearl System builds a new bridge for Chinese traditional agricultural wisdom to reach the global stage and has exemplary significance," said Min Qingwen , head of the Expert Committee on GIAHS under the Ministry of Agriculture and Rural Affairs. He added that the successful heritage application is just the beginning, and continued exploration and promotion of the system's value are needed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Amid the Turmoil, Is Now a Good Time to Buy Tesla Stock?
Tesla (NASDAQ: TSLA) might be the most discussed stock in the history of stocks. You might think there's nothing new to be said -- and that investors should just buy it and hold on. But as someone who has been watching Tesla stock since its IPO in 2010, I think the forces moving the stock have changed a great deal in the last several years -- and I think the bull case for Tesla has some big problems. For starters, Tesla's sales aren't going in the right direction. But there's a deeper reason to think twice about Tesla stock as well. Tesla's car business is going in the wrong direction Not too long ago, it was still possible to believe that huge growth was inevitable for Tesla. The developed world was moving quickly toward a zero-emissions future, and Tesla had the best electric vehicles one could buy -- and it was scaling up to build millions more every year. What could go wrong? A lot, it turned out. Between CEO Elon Musk's foray into right-wing politics, Tesla's aging product line, and the growing number of excellent EVs from other automakers, Tesla's sales have been hit hard. Global sales were down 13% in the first quarter of 2025 from a year earlier. In Europe and China -- arguably the two most critical global markets for EVs right now -- they're down even further so far in the second quarter, while overall sales of EVs continue to rise. Musk's answer has been to make -- or at least talk up -- an aggressive pivot to robotaxis. Tesla has claimed that its service's costs will be far below market leader Waymo's, in large part because Tesla doesn't bother with the expensive lidar sensors that Waymo considers critical to safety. While an optimist might say that cost advantage will lead to market domination, a more realistic view is that Tesla is taking a huge safety risk by sticking with its camera-only system -- a risk that the robotaxi business could end abruptly in a single news cycle if something goes badly wrong. Of course, with Tesla's valuation currently hovering around $1 trillion (a mere 169 times its revenue over the last year), it's reasonable to think that total robotaxi market domination is already built into the company's share price. That's a problem if the robotaxi push goes awry. But the real problem with Tesla stock is that none of that matters much anymore. Tesla's stock price isn't really about its business now Tesla's valuation these days is mostly a reflection of how the popularity and success of Elon Musk is viewed in any given moment. It's very similar to the dynamics behind meme coins, cryptocurrencies that generally lack any purpose (or put another way, any fundamental value) beyond the cultural value they hold and the communities that surround them. As my colleague Anders Bylund recently wrote: Meme coins spotlight the power of community and sentiment in the digital age. Their value is largely driven by social media, celebrity endorsements, and the broader meme culture that thrives on the internet. Tesla does have some fundamental value, of course -- the car and energy-storage businesses, the (maybe) robotaxi business, and the (someday, maybe, perhaps) humanoid-robot business. But the car business, the part that has generated most of Tesla's revenue to date, is trending in the wrong direction. That's a situation that would drive the stocks of most other automakers down to just a few times earnings. It hasn't hit Tesla stock that way -- at least, not yet -- because of Musk's outsized public presence and huge promises. But take a step back: If your hope is to buy Tesla stock now and make a fortune, be aware that ship may have long since sailed. The only reason to buy Tesla now On the other hand, there's certainly a strong community around Tesla -- and a smaller, but still strong, community of those who remain very bullish on the stock and love to discuss its twists and turns. If joining that latter community appeals to you, a very small position in Tesla might still be worthwhile. But as a long-term investment, here in 2025 I think you owe it to yourself to find something sturdier than Tesla stock. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $367,516!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,712!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $669,517!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon. See the 3 stocks » *Stock Advisor returns as of June 2, 2025
Globe and Mail
a day ago
- Globe and Mail
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a significant portion of this price decline is attributed to broader market uncertainties and a volatile macroeconomic environment. The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets. Though the massive tariffs imposed by the United States and China are now on a pause, it is only a temporary suspension, and no one knows what will happen after the 90-day tariff suspension ends. The uncertainty around tariffs and trade production measures remains, slowing down economic growth. Although pharmaceuticals have been exempted from tariffs in the first round, they could be Trump's target in the next round, considering the President's goal to shift pharmaceutical production back to the United States, primarily from European and Asian countries. Trump and the Republican government also continue to stress on the control of drug prices with the latest attempt being his 'most favored nations' policy.' Let's understand AZN's strengths and weaknesses to better analyze how to play the stock in an uncertain macro environment. AZN's Strong Portfolio of Blockbuster Drugs AstraZeneca boasts a diversified geographical footprint as well as a product portfolio with several blockbuster medicines. AstraZeneca now has 16 blockbuster medicines in its portfolio with sales exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza (partnered with Merck [ MRK ]), Calquence and Ultomiris. These drugs are driving the company's top line, backed by increasing demand trends. The company is confident that the growth will continue in 2025. Almost every new product it has launched in recent years has done well. Newer drugs like Wainua, Airsupra, Saphnelo, Datroway (partnered with Daiichi Sankyo) and Truqap are also expected to continue to contribute to top-line growth in 2025. AZN Enjoys Strong Position in the Oncology Space Oncology is AstraZeneca's biggest segment. The company is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Oncology sales (comprising around 41% of AstraZeneca's total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales. The strong oncology performance is being driven by medicines such as Tagrisso, Merck-partnered Lynparza, Imfinzi, Calquence and Daiichi Sankyo-partnered Enhertu. A key new cancer drug approval was that of Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer. The drug has seen a robust launch, recording sales of $430 million in 2024 and $132 million in the first quarter of 2025. In January this year, AstraZeneca and partner Daiichi's drug, Datroway, was approved by the FDA for HR+ HER2- breast cancer, while a regulatory application is under review for EGFR-mutated non-small cell lung cancer (NSCLC). Datroway witnessed encouraging early launch signals in the United States. AstraZeneca expects continued growth of its oncology medicines in 2025, particularly Tagrisso, Enhertu and Imfinzi, despite the incremental impact of the Part D redesign. Several Headwinds to Hurt AZN's Top Line in 2025 The impact of Part D redesign hurt sales of AZN's older drugs, Tagrisso, Lynparza and Ultomiris, as well as newer drugs, Truqap and Wainua, in the United States in the first quarter of 2025, with the trend expected to continue through the rest of the year. AstraZeneca expects Farxiga and Lynparza to be included in the volume-based procurement plans in China in mid-2025, which can hurt sales of these drugs in the country. Pricing and competitive pressure in Europe and generic competition in some emerging markets are expected to hurt sales of some drugs. Brilinta generics are expected to be launched in the United States in 2025. This will hurt sales of the drug. Biosimilar versions of Soliris were launched in the United States in March 2025, which, along with successful conversion to Ultomiris, biosimilar pressure in Europe and unfavorable order timing in certain tender markets, is expected to lead to a continuous decline in sales of Soliris. AstraZeneca is facing ongoing investigations at its China subsidiary. The Chinese authorities are investigating some current and former AstraZeneca employees at its China subsidiary for medical insurance fraud, illegal drug importation and personal information breaches. AZN Stock's Price, Valuation & Estimates AZN stock has risen 8.2% so far this year againsta decrease of 3.1% for the industry. The stock has also outperformed the sector and S&P 500 index, as seen in the chart below. AZN Stock Outperforms Industry, Sector & S&P 500 From a valuation standpoint, AstraZeneca is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 14.93 forward earnings, slightly higher than 14.74 for the industry. However, AZN's stock is trading below its 5-year mean of 18.05. The stock is also much cheaper than other large drugmakers like Eli Lilly LLY and Novo Nordisk NVO. Eli Lilly and Novo Nordisk currently dominate the obesity space. AZN Stock Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $4.47 per share to $4.50 per share over the past 60 days. For 2026, earnings estimates have risen from $4.95 per share to $4.98 per share over the same timeframe. AZN Estimate Movement Consider Buying AZN Stock Despite the potential impact from Part D redesign, AstraZeneca expects total revenues to grow by a high single-digit percentage at CER in 2025. Growth momentum in Oncology and CVRM(cardiovascular, renal and metabolism) segments is expected to continue in 2025. However, in Rare Disease, though AstraZeneca expects growth in 2025, it will be at a slower pace than in 2024. Regarding the potential impact of tariffs, AstraZeneca had a positive tone on the first-quarter conference call. The company said it has limited commercialized finished medicines imported to the United States from China, which lowers its exposure to potential China tariffs on pharmaceuticals. It also has a substantial and growing manufacturing footprint in the United States, and the majority of its medicines sold in the United States are manufactured domestically. It does import some medicines from Europe but believes that if tariffs on pharmaceutical imports from Europe are implemented in a similar range as other industries, it will be manageable and allow the company to remain within its guidance range for EPS. In 2025, AstraZeneca expects core EPS to increase by a low double-digit percentage. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. AstraZeneca expects to generate$80 billion in total revenues by 2030, a significant increase from the $54 billion it generated in 2024. By the said time frame, AstraZeneca plans to launch 20 new medicines, with nine new medicines already launched/approved. It believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. The company is also on track to achieve a mid-30s percentage core operating margin by 2026 Considering AZN's growth prospects, investors may take advantage of the recent dip and consider buying this Zacks Rank #2 (Buy) stock, more so as it is trading below its five-year mean. Consistently rising estimates also indicate analysts' optimistic outlook for growth. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report
Globe and Mail
2 days ago
- Globe and Mail
While Bitcoin Hits a New Price Record, Critics Still Have These Warnings for Crypto Investors
Bitcoin (CRYPTO: BTC) may have hit a new all-time high of $112,000 in May, but it's not out of the woods quite yet. Already, Bitcoin has retreated back down to the $105,000 level, and there are some critics warning about a further decline in price. While the long-term outlook for Bitcoin might be bullish, there could be quite a bit of uncertainty and volatility over the second half of 2025. Here are three key factors keeping the Bitcoin skeptics up at night. Tariff and trade uncertainty As long as tariffs continue to dominate the headlines, they will continue to have a direct impact on how investors view the crypto market. As a result, it's been a see-saw year for Bitcoin. After hitting an all-time high in January, Bitcoin dropped as low as $75,000 after President Donald Trump announced the new Liberation Day tariffs on April 2. Bitcoin has subsequently recovered, but every week seems to bring some new twist or turn in the tariff debate. The newest factor is the worsening state of the trade negotiations involving the U.S. and China. At one time, it looked like some kind of trade deal might be worked out by mid-summer. Now, it looks like the two sides are further apart than ever. So how will Bitcoin investors react? If they view Bitcoin as a safe haven asset, they might move even more money into Bitcoin, thereby boosting its price. However, if they view Bitcoin as a risky and volatile digital asset, then they might sell off, just as they did in April. Unfinished business in Washington When President Trump came into office in January, the future looked very bright indeed for Bitcoin. New crypto legislation looked like it would be ready to sign soon, and crypto enthusiasts were excited about upcoming Bitcoin initiatives from the Trump White House. However, five months into the presidency, and there's still a lot of unfinished business. Take the Strategic Bitcoin Reserve, for example. Yes, Trump signed an executive order for its creation in March, but it delivered much less punch than many people expected. Most importantly, the executive order failed to outline how the government planned to buy Bitcoin in the future. As a result, investors are still waiting on some form of legislation, such as the BITCOIN Act proposed by Sen. Cynthia Lummis (R-Wyo.), that will precisely outline a mechanism for buying more Bitcoin. On top of all that, there are now questions swirling around the Trump family's connections to Bitcoin. At the very least, there appear to be potential conflicts of interest. For example, Donald Trump's media company -- Trump Media & Technology Group -- recently divulged plans to buy $2.5 billion worth of Bitcoin. And members of the Trump family now have interests in a variety of Bitcoin-related projects. The four-year Bitcoin cycle Historically, Bitcoin has followed a fairly predictable pattern of boom and bust. The four-year Bitcoin cycle starts with a period of quiet accumulation, followed by a period of rapid growth. This leads to a Bitcoin bubble filled with hype and speculation. After that comes the crash. For example, the 2020-2021 rally that saw Bitcoin hit a (then) all-time high of $69,000 was quickly followed by a disastrous market crash that saw it lose 65% of its value in 2022. And the same pattern may be happening again. If history is any guide, then the final phase of the Bitcoin cycle could be arriving soon. Thus, even if Bitcoin soars to $150,000 this year, it might have a hard time holding on to those gains heading into 2026. If you'd have waited until now to buy Bitcoin, you might be buying at or close to the top of the market. By the end of 2025, it might already be too late. Only a 22% chance of failure? The good news is that most Bitcoin investors are remarkably bullish these days. According to online prediction markets, Bitcoin only has a 22% chance of falling below the $70,000 price level, and only a 16% chance of falling below the $60,000 price level. Long gone are the days when people regularly prognosticated that Bitcoin could fall all the way to zero. That being said, investors still need to be aware of the risks of investing in Bitcoin. The price of Bitcoin never goes straight up. It is highly volatile, filled with many peaks and valleys. If you don't have firm convictions about Bitcoin, it's remarkably easy to buy high and sell low. When it comes to Bitcoin, it's best to keep a long-term perspective. Bitcoin has never been a tariff-proof, inflation-proof, or recession-proof asset. But over a long enough time horizon, it continues to be the top-performing asset in the world. The only catch is that you have to be willing to hold on to it, through good times and bad. Should you invest $1,000 in Bitcoin right now? Before you buy stock in Bitcoin, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
